Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STORM: Tailoring Antibiotic Duration for Respiratory Tract Infections
NCT06581367Phase 4Not yet recruiting
- Sponsor
- IDIAPJGol
- Start
- Oct 2025
- Primary completion
- Mar 2027
01
Overview
Phase 4, randomised, open-label trial in acute respiratory tract infection (ARTI), acute rhinosinusitis (ARS), community acquired pneumonia (CAP) and 2 more (2 arms), sponsored by IDIAPJGol. Primary endpoint: Clinical efficacy at Day 14. Planned start Oct 2025; status: not yet recruiting.
02
Conditions
acute respiratory tract infection (ARTI)acute rhinosinusitis (ARS)community acquired pneumonia (CAP)acute bronchitischronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06581367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581367.